276 results about "Acute liver injury" patented technology

The invention discloses a Chinese pharmaceutical composition for treating hepatitis and fatty liver, which comprises cornus officinalis, oriental wormwood, cape jasmine, baikal skullcap root, plantain seeds, clematis stem, polyporus umbellatus, poria cocos, rush pith, curcuma aromatica, licorice root, cyperus tuber, dandelion, white atractylodes rhizome, magnolia bark, Bupleurum root, chicken's gizzard-skin, green tangerine orange peel, banksia rose, malt, isatic root, haw, turtle shell, burred tuber, Loranthus mulberry mistletoe, talcum powder, bitter orange, zedoary, fleece-flower root, root of herbaceous peony, medicated leaven, Chinese angelica root, rhubarb horsetails.

Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs, named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD), are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. For example, recombinant proteins consisting of suppressor of cytokine signaling 3 protein (CP-SOCS3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, CP-SOCS3 fusion proteins expressed in bacteria were hard to purify in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTD) have been developed in this art. This is accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences satisfied for each critical factor. In addition, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed CP-SOCS3 proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-cancer agents in the treatment of hepatocellular carcinoma. Since SOCS3 is frequently deleted in and loss of SOCS3 in hepatocytes promotes resistance to apoptosis and proliferation, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for the treatment of hepatocellular carcinoma. The results support this reasoning: treatment of hepatocellular carcinoma cells with iCP-SOCS3 results in reduced cancer cell viability, enhanced apoptosis and loss of cell migration/invasion potential. Furthermore, iCP-SOCS3 inhibits the growth of hepatocellular carcinoma in a subcutaneous xenografts model. In the present invention with iCP-SOCS3 fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTD may provide novel protein therapy against hepatocellular carcinoma.

In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance. Protein transduction exploits the ability of some cell-penetrating peptide (CPP) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic CPPs—named membrane translocating sequence (MTS), membrane translocating motif (MTM) and macromolecule transduction domain (MTD)—are able to deliver biologically active proteins into a variety of cells and tissues. Various cargo proteins fused to these CPPs have been used to test the functional and/or therapeutic efficacy of protein transduction. Previously, recombinant proteins consisting of suppressor of cytokine signaling 3 (SOSC3) fused to the fibroblast growth factor (FGF) 4-derived MTM were developed to inhibit inflammation and apoptosis. However, this SOCS3 fusion proteins expressed in bacteria cells were hard to be purified in soluble form. To address these critical limitations, CPP sequences called advanced MTDs (aMTDs) have been developed in this art. The development of this art has been accomplished by (i) analyzing previous developed hydrophobic CPP sequences to identify specific critical factors (CFs) that affect intracellular delivery potential and (ii) constructing artificial aMTD sequences that satisfy each critical factor. Furthermore, solubilization domains (SDs) have been incorporated into the aMTD-fused SOCS3 recombinant proteins to enhance solubility with corresponding increases in protein yield and cell-/tissue-permeability. These recombinant SOCS3 proteins fused to aMTD/SD having much higher solubility/yield and cell-/tissue-permeability have been named as improved cell-permeable SOCS3 (iCP-SOCS3) proteins. Previously developed SOCS3 recombinant proteins fused to MTM were only tested or used as anti-inflammatory agents to treat acute liver injury. In the present art, iCP-SOCS3 proteins have been tested for use as anti-angiogenic agents. Since SOCS3 is known to be an endogenous inhibitor of pathological angiogenesis, we reasoned that iCP-SOCS3 could be used as a protein-based intracellular replacement therapy for inhibiting angiogenesis in tumor cells. The results demonstrated in this art support this following reasoning: Cancer treatment with iCP-SOCS3 results in reduced endothelial cell viability, loss of cell migration potential and suppressed vascular sprouting potentials. In the present invention with iCP-SOCS3, where SOCS3 is fused to an empirically determined combination of newly developed aMTD and customized SD, macromolecule intracellular transduction technology (MITT) enabled by the advanced MTDs may provide novel protein therapy against cancer cell-mediated angiogenesis.

The invention discloses application of lactobacillus plantarum to preparation of a product with a liver protecting function. The preservation number of the lactobacillus plantarum C88 is CCTCC NO: M 209254. The product is food or a health care product or a drug. The main functions of the product include reduction of organism oxidative stress and inflammatory reactions caused by acute liver injuries, promotion of intactness of the intestinal barrier function and effective relief of acute liver injury symptoms. The lactobacillus plantarum C88 or a fungal preparation thereof is taken every day to replace drugs to protect the liver against injuries. The lactobacillus plantarum C88 can serve as functional probiotics to be applied to the fields of food, health care products and drugs and has broad application prospects.

The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with plerixafor and G-CSF

The irigenin has protective function on the mouse instant liver hurt induced by D-galactosamine,D-GalN, has protective function on the mouse instant liver hurt induced by CC14, has cure function on big mouse liver fiber caused by composite factors, and high restrain function on the liver cancer cell. Therefore, irigenin can be used to prepare relative medicine.

The invention discloses application of andrographolidume to preparing medicine for treating acute liver injury. The andrographolidume can remarkably inhibit liver injury induced by semen canavaliae A, the liver cell apoptosis induced by the ssemen canavaliae A and inflammatory response of liver, and can also be used for treating the liver injury induced by the semen canavaliae A. The invention firstly provides the evidence of the andrographolidume for treating the liver injury induced by the semen canavaliae A in an animal model, definitudes that the liver cell apoptosis caused by the semen canavaliae A is inhibited by inhibiting excessive active oxygen species caused by the semen canavaliae A, and prompts that the andrographolidume has the protection function on the acute liver injury in clinical.

The invention discloses an application of a ferroptosis inhibitor in preparation of a medicine for treating an acute liver injury. A ferroptosis inhibitor is pretreated to remarkably reduce levels ofglutamic-pyruvic transaminase ALT and glutamic oxalacetic transaminase AST in serum after the acute liver injury induced by sodium thiosulfate TAA; an MDA content in liver tissues after the TAA-induced acute liver injury is reduced, and the contents of reduced glutathione GSH and glutathione peroxidase GSH-PX in the liver tissues are increased; infiltration of inflammatory cells in the TAA-inducedacute liver injury to a liver is reduced; and a protective effect of the ferroptosis inhibitor on the TAA-induced acute liver injury is related to inhibition of hepatocyte ferroptosis, and ferroptosis marker gene glutamic acid/cystine reverse transporter xCT and Gpx4 glutathione peroxidase 4 in a TAA-induced acute liver injury model can be remarkably improved by the ferroptosis inhibitor.

The invention discloses application of peripheral blood mononuclear cell activation inhibitors to preparing a medicine for treating and/or preventing acute hepatic failure, and further provides the medicine for treating and/or preventing the acute hepatic failure. The medicine is a preparation, the peripheral blood mononuclear cell activation inhibitors are used as active substances for the preparation, and pharmacologically acceptable excipients or auxiliary components are added into the peripheral blood mononuclear cell activation inhibitors to prepare the preparation. The application and the medicine have the advantages that the fact that activation of mononuclear cells can be effectively inhibited is proved, accordingly, acute hepatic injury can be effectively treated and prevented, a novel option can be provided for clinically treating the acute hepatic injury, and the medicine has an excellent application prospect.

The invention discloses a black tea fungus beverage. The black tea fungus beverage is prepared from water, fermented black tea juice, black tea powder, concentrated lemon juice, vitamins C, white granulated sugar, high fructose corn syrup, sodium benzoate, sodium citrate, citric acid monohydrate, malic acid, acesulfame k, sucralose and essence. The black tea fungus beverage is characterized in that the fermented black tea juice is prepared in the mode that Assam tea is brewed, anaerobic fermentation is carried out through mixed strains of lactobacillus plantarum LP28, lactobacillus plantarum LP198, streptococcus thermophilus GRX02 and lactobacillus lactis LLD965, and then inactivation is carried out. Compared with the prior art, the black tea fungus beverage contains the inactivated lactobacillus plantarum LP28, the inactivated lactobacillus plantarum LP198 and the inactivated lactobacillus lactis LLD965, immune responses can be adjusted through the inactivated probiotics, and the anti-tumor function and the function of treating ethyl-alcohol-induced acute liver injuries are achieved.

The invention discloses application of clostridium butyricum in preparation of medicines for treating and/or preventing acute liver injury, belonging to the field of medicines. According to the application, the clostridium butyricum is capable of relieving oxidative stress response in the acute liver injury by improving the activity of superoxide dismutase and catalase as well as reducing the content of malonaldehyde in the liver tissue, and can reduce the accumulation of IL-1beta, IL-6 and TNF-alpha in the liver tissue at the same time; therefore, the clostridium butyricum has functions of resisting oxidative stress and resisting inflammatory response, and is capable of effectively treating liver injury so as to restore the normal liver functions. Furthermore, the main metabolite of the clostridium butyricum is butyric acid, so that the clostridium butyricum is beneficial to the protection of the liver.

The invention relates to an application of a novel compound in preparation of liver protection drugs or health care products and further relates to a method for preparing the compound through extraction, separation and purification from Sabia parviflora. The pharmacological research indicates that the novel compound can reduce the content of ALT (alanine aminotransferase) and AST (aspartic transaminase) in serum of a CC14 induced acute liver injury model mouse, a D-galactosamine induced acute liver injury model mouse and an ethanol induced liver injury model mouse, reduce the content of MDA (methylene dioxyamphetamine) in liver tissue and enhance SOD (superoxide dismutase) activity of the liver, has a remarkable protection effect on liver injury and is expected to be developed into new drugs or health care products with the liver protection function.

The invention provides abalone viscera acidic polysaccharose. According to the abalone viscera acidic polysaccharose, a main chain comprises rhamnose and glucuronic acid, wherein a C-2 position or C-3 position of the rhamnose in the main chain is subjected to sulphating; and the rhamnose in the main chain is connected with the rhamnose or galactose to form a branched chain structure. The abalone viscera acidic polysaccharose which is extracted from abalone viscera can promote the proliferation of hepatoma carcinoma cells (HepG2) in vitro obviously, and has a certain effect of dose dependency; and experiments of studying a repair effect of the abalone viscera acidic polysaccharose on the HepG2 cells which are subjected to oxidative damage and on rat hepatic tissues which are subjected to acute hepatic damage caused by carbon tetrachloride in vivo indicate that the abalone viscera acidic polysaccharose can be used as a functional factor for protecting liver.

The invention relates to a method for separating and preparing ursolic acid methyl ester from dracocephalum heterophyllum benth. The method comprises steps as follows: (1), dracocephalum heterophyllum benth is cut into sections and subjected to reflux extraction by ethyl alcohol to obtain an extracting solution; and the extracting solution is concentrated under reduced pressure to obtain extracts; (2), the extracts are extracted by ethyl acetate under the ambient temperature condition to obtain an extract liquid, and the extract liquid is concentrated under reduced pressure to obtain crude extracts of ursolic acid methyl ester; (3), the crude extracts of ursolic acid methyl ester are dissolved in ethyl acetate, silica gel is added, the mixture is stirred and mixed, silica gel columns are fed with a dry method twice after the solvent of ethyl acetate volatilizes, and purer ursolic acid methyl ester is obtained after concentration under reduced pressure; and (4), the purer ursolic acid methyl ester is dissolved and crystallized for impurity removal and then filtered to obtain ursolic acid methyl ester crystals. The method is simple, simple and convenient to operate and high in separation efficiency and separation purity; and meanwhile, the ursolic acid methyl ester crystals obtained with the method can be applied to treatment of tumor and acute liver injury diseases.

The invention discloses a method for inducing and differentiating human amniotic epithelial stem cells into liver cells with biological functions. The method includes the steps: 1) separating, culturing, amplifying and identifying the human amniotic epithelial stem cells, and marking the human amniotic epithelial stem cells by GFP (green fluorescent protein); 2) in-vitro induction differentiation:using third-seventh-generation human amniotic epithelial stem cells with GFP markers for test, selecting a first system containing inducing media I, II and III or a second system containing inducingmedia IV, V and VI to perform induced differentiation, and inducing and differentiating the cells by the first system (inducing time is 14-15 days) or the second system (inducting time is 22-23 days)to obtain liver sample cells which can express specific markers of the liver cells and have normal liver cell functions; 3) in-vivo transplantation: transplanting the liver sample cells generated by inducing into a body of an acute liver injury mouse. Acute liver injury can be obviously relieved, the liver function of the mouse is restored, and the survival rate of the mouse is increased.

The invention discloses preparation and an application of a mulberry compound microcapsule. Mulberry, semen cassia, sea-buckthorn and mulberry leaf are taken as core materials; arabic gum and modified starch as taken as wall materials; the core materials are mixed with the wall materials at the mass ratio of 1 to 1; and the mixture contains the following raw materials: 5-10 parts of semen cassia, 20-25 parts of sea-buckthorn, 5-10 parts of liquorice, 45-55 parts of mulberry, 10-15 parts of mulberry leaves, 0.25% of NaCl, 0.125% of Vc, 2% of succinylated monoglycerides, 2% of porous starch and 2% of beta-cyclodextrin. The mulberry compound microcapsule which is enveloped once is adsorbed by the porous starch and beta-cyclodextrin, so as to prepare a double-enveloped mulberry compound microcapsule; and the mulberry compound microcapsule is sterilized by virtue of a microwave. The novel double-enveloped mulberry compound microcapsule product is moderate in particle size, good in sense, high in stability, moisture-proof and hygroscopic; and the mulberry compound microcapsule has a protecting effect on acute liver injuries in mice caused by CC14 and ethyl alcohol, and has wide application value.